. 2011 Jun 10;13(8):916–922. doi: 10.1093/neuonc/nor055

Table 4.

Representative reported results of SRS, FSRT, FPT, and HSRT for nonfunctioning pituitary adenoma

Author, year	Therapy, device	Patient number	Marginal or total dose (mean, range)	Treatment outcome (local control rate, visual disorders, hypopituitarism)	Median follow-up (months)
Kobayashi 2009⁹	SRS, GK	60	14.1 Gy/1 Fr (none)	97% (≥3y), 4%, 8%	63
Mingione 2006¹⁰	SRS, GK	90	18.5 Gy/1 Fr (5.0–25.0 Gy/1Fr)	92% (4y), 0%, 25%	45
Pollock 2008¹¹	SRS, GK	62	16.0 Gy/1 Fr (11.0–20.0 Gy/1Fr)	95 % (3y, 7y), 0%, 32%	64
Snead 2008¹⁷	FSRT, Linac	59	45.0 Gy/25 Fr (43.0–50.4 Gy/25 Fr)	98% (10y), 1%, 35% (including functioning PA)	80
Minniti 2006¹⁸	FSRT, Linac	67	45.0 Gy/25 Fr (45.0–50.0 Gy/25–30 Fr)	98% (3y), 1%, 22% (including functioning PA)	32
Ronson 2006¹⁹	FPT, Proton	24	50.4 CGE/28Fr or 54.0 CGE/30Fr (50.4–55.9 CGE/28–30 Fr)	100% (4y), 23%, 28% (including functioning PA)	47
This study 2010	HSRT, CK	100	21.0 Gy/3Fr or 25.0 Gy/5 Fr (17.0–25.0 Gy/3–5 Fr)	98 % (3y), 1%, 2%	33

Abbreviations: SRS, stereotactic radiosurgery; FSRT, fractionated stereotactic radiotherapy; FPT, fractionated proton therapy; HSRT, hypofractionated stereotactic radiotherapy; GK, Gamma Knife; Fr, fractions; y, years; PA, pituitary adenoma; CK, CyberKnife; CGE, cobalt-gray equivalent.